Analysis of N- and O-glucuronides of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine

被引:60
作者
Carmella, SG [1 ]
Le, KA [1 ]
Upadhyaya, P [1 ]
Hecht, SS [1 ]
机构
[1] Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA
关键词
D O I
10.1021/tx015584c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is a tobacco-specific lung carcinogen which may play an important role as a cause of lung cancer in smokers. NNK is extensively metabolized to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), which like NNK is a potent pulmonary carcinogen. NNAL in turn is glucuronidated, and both NNAL and its glucuronides are excreted in human urine. Previous studies have clearly demonstrated the presence in human urine of 4-(methylnitrosamino)-1-(3-pyridyl)-1-(O-beta-D-glueopyranuronosyl)-butane (NNAL-O-Gluc), but did not exclude the presence of 4-(methylnitrosamino)-1-(3-pyridyl-N-beta-D-glueopyranuronosyl)-1-butanolonium inner salt (NNAL-N-Gluc). In this study, we quantified NNAL, NNAL-N-Gluc, and NNAL-O-Gluc in the urine of smokers, snuff-dippers, and people who used the oral tobacco product "toombak". The presence of NNAL-N-Gluc in the urine of toombak users was confirmed by LC-ESI-MS/MS. In smokers' urine, NNAL-N-Gluc, NNAL-O-Gluc, and NNAL comprised (mean +/- SD) 26.5 +/- 6.2, 32.1 +/- 17.6, and 41.4 +/- 16.6%, respectively, of total NNAL. In snuff-dippers' urine, the corresponding figures were 13.6 +/- 5.1, 46.6 +/- 11.7, and 36.6 +/- 9.3%. NNAL-N-Gluc comprised 50 +/- 25% of total glucuronidated NNAL in smokers and 24 +/- 12% in snuff-dippers. This difference was significant (P = 0.01), suggesting that smoking induces glucuronidation of NNAL. The results of this study demonstrate that NNAL-N-Gluc contributes substantially to NNAL-glucuronides in human urine. These results are important for a clearer understanding of mechanisms of detoxification of NNK in humans.
引用
收藏
页码:545 / 550
页数:6
相关论文
共 39 条
[31]  
Ren Q, 2000, DRUG METAB DISPOS, V28, P1352
[32]  
RIVENSON A, 1988, CANCER RES, V48, P6912
[33]   BILIARY-EXCRETION OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE IN THE RAT [J].
SCHULZE, J ;
RICHTER, E ;
BINDER, U ;
ZWICKENPFLUG, W .
CARCINOGENESIS, 1992, 13 (11) :1961-1965
[34]   Tobacco-specific nitrosamines [J].
Spiegelhalder, B ;
Bartsch, H .
EUROPEAN JOURNAL OF CANCER PREVENTION, 1996, 5 :33-38
[35]   Human UDP-glucuronosyltransferases: Metabolism, expression, and disease [J].
Tukey, RH ;
Strassburg, CP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2000, 40 :581-616
[36]   Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse [J].
Upadhyaya, P ;
Kenney, PMJ ;
Hochalter, JB ;
Wang, MY ;
Hecht, SS .
CARCINOGENESIS, 1999, 20 (08) :1577-1582
[37]   Preparation of pyridine-N-glucuronides of tobacco-specific nitrosamines [J].
Upadhyaya, P ;
McIntee, EJ ;
Hecht, SS .
CHEMICAL RESEARCH IN TOXICOLOGY, 2001, 14 (05) :555-561
[38]   Formation and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers in vitro in mouse, rat and human tissues [J].
Upadhyaya, P ;
Carmella, SG ;
Guengerich, FP ;
Hecht, SS .
CARCINOGENESIS, 2000, 21 (06) :1233-1238
[39]   Drug interactions with tobacco smoking - An update [J].
Zevin, S ;
Benowitz, NL .
CLINICAL PHARMACOKINETICS, 1999, 36 (06) :425-438